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Epidemiological studies indicate that elevated alkaline phosphatase activity is associated
with increased cardiovascular disease risk. Other epidemiological data demonstrate that
mothers giving multiple childbirths (multipara) are also at increased risk of developing
late-onset cardiovascular disease. We hypothesized that these two associations stem
from a common cause, the insufficient plasma level of the ectopic mineralization
inhibitor inorganic pyrophosphate, which is a substrate of alkaline phosphatase.
As alkaline phosphatase activity is elevated in pregnancy, we hypothesized that
pyrophosphate concentrations decrease gestationally, potentially leading to increased
maternal vascular calcification and cardiovascular disease risk in multipara. We
investigated plasma pyrophosphate kinetics pre- and postpartum in sheep and at
term in humans and demonstrated its shortage in pregnancy, mirroring alkaline
phosphatase activity. Next, we tested whether multiparity is associated with increased
vascular calcification in pseudoxanthoma elasticum patients, characterized by low
intrinsic plasma pyrophosphate levels. We demonstrated that these patients had
increased vascular calcification when they give birth multiple times. We propose that
transient shortages of pyrophosphate during repeated pregnancies might contribute to
vascular calcification and multiparity-associated cardiovascular disease risk threatening
hundreds of millions of healthy women worldwide. Future trials are needed to assess if
gestational pyrophosphate supplementation might be a suitable prophylactic treatment
to mitigate maternal cardiovascular disease risk in multiparous women.
Keywords: cardiovascular disease risk, ectopic mineralization, alkaline phosphatase, pregnancy,
pseudoxanthoma elasticum, vascular calcification, plasma inorganic pyrophosphate, sheep
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INTRODUCTION
Recent epidemiological studies demonstrated that multiparous
women have an increased risk for developing cardiovascular
disease manifesting decade(s) after their pregnancies (Sanghavi
et al., 2016; Kim et al., 2018; Oliver-Williams et al., 2019;
Tanigawa et al., 2019). The molecular mechanism underlying
this severe health-care problem is still elusive. Interestingly, in
independent epidemiological studies high alkaline phosphatase
levels were associated with coronary artery calcification (Panh
et al., 2017), and future incidence of cardiovascular disease
(Kunutsor et al., 2015; Kabootari et al., 2018) especially in
young (<55 years of age) patients (Li et al., 2014; Rahmani
et al., 2019). Alkaline phosphatase is the major degrading
enzyme of inorganic pyrophosphate, a potent inhibitor of
vascular calcification. Alkaline phosphatase activity is known to
increase during pregnancy (Sussman et al., 1968; Okamoto et al.,
1990). Therefore, we hypothesized that inorganic pyrophosphate
concentration declines during pregnancy, due to increased
alkaline phosphatase activity, contributing to the development
of pregnancy-related late-onset maternal cardiovascular disease.
According to our hypothesis, cardiovascular disease risk
emerging in the two sets of independent epidemiological studies
stems from a common cause, insufficient plasma inorganic
pyrophosphate concentration.
Circulation provides precursors for the formation and
remodeling of bones, a process under tight spatiotemporal
regulation. Calcifying agents are present at high concentrations
in the circulation, ready to start and propagate mineralization.
Meanwhile, a network of active processes prevents the
mineralization of arterial walls and other soft tissues (Back
et al., 2018). One key anti-mineralization factor is inorganic
pyrophosphate (Li et al., 2016a; Favre et al., 2017), present
in the plasma at low micromolar concentrations and reduced
in rare recessive ectopic mineralization disorders, such as
generalized arterial calcification of infancy (GACI) and
pseudoxanthoma elasticum (PXE). GACI is mostly caused by
loss-of-function mutations of the gene coding for ectonucleotide
pyrophosphatase phosphodiesterase 1 (ENPP1), which converts
extracellular ATP into AMP and inorganic pyrophosphate.
Lack of functional ENPP1 leads to the virtual absence
of systemic inorganic pyrophosphate (Rutsch et al., 2003)
resulting in severe in utero onset arterial calcification with high
mortality. The majority of plasma inorganic pyrophosphate
is generated from ATP provided by ABCC6 expressed
primarily in hepatocytes (Jansen et al., 2013, 2014; Pomozi
et al., 2013). Biallelic inactivating mutations of ABCC6 cause
PXE, a disease characterized by reduced plasma inorganic
pyrophosphate concentrations and milder vascular calcification
compared to GACI.
We previously demonstrated the crucial role of inorganic
pyrophosphate in preventing vascular calcification in the
mouse models of PXE and GACI (Dedinszki et al., 2017).
Interestingly, in the GACI mouse model, treating dams solely
during gestation with inorganic pyrophosphate was sufficient
to alleviate vascular calcification in their offspring (Dedinszki
et al., 2017). Furthermore, ectopic calcification in PXE and
GACI mouse models is effectively prevented by an inorganic
pyrophosphate analog bisphosphonate (Li et al., 2016b, 2018).
In both PXE and GACI, mothers are heterozygous carriers
of the mutations without any apparent clinical phenotype.
The current treatment for GACI in humans is postnatal
bisphosphonates, increasing patient survival. In one case
report, bisphosphonate treatment of a pregnant mother led
to reduced vascular calcification in the fetus (Bellah et al.,
1992). Altogether, the efficiency of maternal treatment during
pregnancy to rescue vascular calcification in the offspring
has been demonstrated in mice and humans. The efficacy
of maternal in utero treatment with inorganic pyrophosphate
and bisphosphonates in preventing vascular calcification of the
F1 generation is indicative of insufficient maternal gestational
inorganic pyrophosphate levels.
Our current work aims to demonstrate that inorganic
pyrophosphate levels decline in healthy pregnancy, and low
inorganic pyrophosphate concentrations may contribute
to increased vascular calcification and thus to elevated
cardiovascular disease risk. We propose that inorganic
pyrophosphate supplementation during pregnancy could be a
potential therapeutic approach to circumvent pregnancy-related
late-onset maternal cardiovascular disease.
METHODS
Animal Studies
The study was conducted at the MSU Sheep Teaching and
Research Center. Eight sheep (Polypay × Dorset), pregnant with
twins, were studied from gestational day (GD) 55 to postpartum
day (PD) 40. Blood samples were collected between 8 and 10 am
except for postnatal day 1, which was collected at 2.8 ± 3.8 h post-
delivery. Eight non-pregnant adult sheep (Polypay × Dorset)
were used as control. Pregnant sheep were housed indoors
and their total mixed ration adjusted to energy requirements
for pregnancy and lactation (National Research Council, 2007)
as previously described (Gingrich et al., 2019). Offspring were
housed with their mothers. After postnatal day 7, offspring had
ad libitum access to grain creep feed. Non-pregnant sheep were
kept outdoors on pasture with shade. All animals had ad libitum
access to water. One female lamb in trio 4 was euthanized at
postnatal day 15 due to an infection.
Healthy Human Subjects
Blood samples were obtained from healthy pregnant women
(20–40 years of age) undergoing scheduled Cesarean section
at Sparrow Hospital, Lansing, MI, United States. Exclusion
criteria included pregnancy complications, such as preterm
birth, preeclampsia, and gestational diabetes. Blood samples
from healthy non-pregnant women (20–40 years of age) were
also collected. Exclusion criteria included calcification, bone or
rheumatological disorder, cancer, diabetes or hypertension.
Pseudoxanthoma Elasticum Patients
The study was part of the phenotyping in the French PXE
cohort (ClinicalTrials.gov, NCT01446380) from 2008 to October
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25, 2019. PXE diagnosis was confirmed on distinctive skin
lesions, dermal elastorrhexis, ophthalmological signs and/or two
mutations of the ABCC6 gene (Legrand et al., 2017). Lower
limb artery calcification was determined using unenhanced
computed tomography (CT) as described by Chowdhury et al.
(2017). Arterial tree of each lower limb was divided into
aortoiliac, femoro-popliteal, and crural segments and scored.
Lower limb artery calcification was calculated as the sum of
all segmental scores of both legs normalized by the total
arterial lengths.
Platelet Free Plasma Preparation and
Inorganic Pyrophosphate Determination
Blood was collected in Vacutainer CTAD tubes with 50 µl
15% K3EDTA, as described previously (Dedinszki et al., 2017).
Plasma was separated (1,000 × g 4◦C, 10-min centrifugation),
and platelet-free plasma was prepared (2,200 × g 4◦C 30-
min centrifugation in Centristart R© 300.000 MW filter tubes).
First, inorganic pyrophosphate was converted into ATP by ATP
sulfurylase (NEB) in the presence of APS, and then ATP was
determined using bioluminescence (BacTiter Glo, Promega).
inorganic pyrophosphate concentration was calculated using
standards and correction for ATP concentrations (Dedinszki
et al., 2017). Samples with hemolysis were excluded.
Statistics
Data were analyzed using GraphPad Prism 8.3.0. and, depending
on normality, shown with means ± SD or medians and 25th–75th
interquartiles. We used unpaired two-tailed t-test with Welch’s
correction for healthy women and unpaired non-parametric two-
tailed Mann-Whitney test for PXE patients except for age in
PXE patients where significance was determined using a two-
tailed unpaired t-test. Animal groups were compared using
multiple comparisons of the paired data with mixed effect
models not assuming sphericity and concomitant Sidak’s multiple
comparisons. Significance was accepted at p < 0.05.
Study Approval
All sheep procedures were approved by the Institutional
Animal Care and Use Committee of Michigan State University.
Euthanasia was conducted on one animal due to an injury-
related infection independent of the present study. The
euthanasia was performed by a Campus Animal Resource
(CAR) veterinarian via a barbiturate overdose as per the
American Medical Veterinarian Association (AMVA) guidelines.
All procedures on healthy human individuals at Sparrow Hospital
and Michigan State University (IRB: 17-1359) was approved by
the Institutional Review Board. All procedures on PXE patients
were approved by the Institutional Research Committee of the
University Hospital of Angers. The study on PXE patients was
performed as a part of the protocol of phenotyping of French
PXE cohort (ClinicalTrials.gov, Identifier: NCT01446380). All
procedures involving human participants were in accordance
with the ethical principles of the Helsinki declaration. Written
informed consent was obtained from all participants prior to




During Pre- and Postpartum in Sheep
As alkaline phosphatase activity is known to increase during
pregnancy and inorganic pyrophosphate is an established
substrate of alkaline phosphatase, we hypothesized that plasma
inorganic pyrophosphate concentrations are decreased during
pregnancy. Therefore, we sought to study plasma inorganic
pyrophosphate kinetics pre- and postpartum in an animal model.
Since current inorganic pyrophosphate determinations require
high blood volumes relative to rodent size, sheep were chosen
for their larger body weight and longer gestation (∼147 days).
This allowed multiple samplings in a longitudinal study to
follow plasma inorganic pyrophosphate concentrations. Non-
pregnant control sheep had a plasma inorganic pyrophosphate
level of 1.14 ± 0.26 µM (Figure 1A), similar to that of
rodents and humans (Dedinszki et al., 2017). This control
group was compared to a cohort of sheep pregnant with twins,
monitored throughout gestation and lactation. We observed
a progressive decrease of plasma inorganic pyrophosphate
concentrations during pregnancy, with a nadir at gestational
day 140, shortly before term. Variable maternal inorganic
pyrophosphate concentrations were detected on the day of
birth and levels gradually increased postpartum, reaching the
plasma inorganic pyrophosphate levels of control sheep by
postpartum day 30.
We also monitored the plasma inorganic pyrophosphate
concentration in the 16 newborn lambs on the same postnatal
days (Figure 1B). Similar to their mothers, the newborns had
variable but low plasma inorganic pyrophosphate concentrations
on postnatal day 1. Within 7 days after birth, plasma
inorganic pyrophosphate levels increased to concentrations
detected in non-pregnant adult sheep. On postnatal day 1,
males had lower inorganic pyrophosphate concentrations than
females (0.26 ± 0.22 and 0.82 ± 0.27 µM, respectively),
but this sex-dependent difference disappeared by postnatal
day 7 (Figure 1C). Within sheep families (trios constituted
by a mother and its twins), inorganic pyrophosphate kinetics
showed a similar pattern, with dams lagging behind their lambs
(Supplementary Figure 1).
Plasma Inorganic Pyrophosphate
Concentration Is Decreased in Healthy
Human Pregnancy
Our results in the sheep suggested that the plasma inorganic
pyrophosphate decrease during pregnancy might be a general
physiological phenomenon relevant to other species as well.
To test this hypothesis in humans, we compared plasma
inorganic pyrophosphate concentrations between non-pregnant
(n = 18; age = 34.6 ± 4.9 year) and pregnant women
(n = 13; age = 30.4 ± 5.6 year) at term before their scheduled
Cesarean-section. Healthy pregnant women had significantly
lower plasma inorganic pyrophosphate concentrations than
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FIGURE 1 | Plasma inorganic pyrophosphate changes dynamically in sheep pre- and postpartum. (A) Plasma inorganic pyrophosphate concentration of pregnant
sheep between gestational day 55 and postpartum day 40 (n = 8, closed circles, white bars) compared to non-pregnant adult females (n = 8, closed squares, gray
bar). (B) Plasma inorganic pyrophosphate concentration of lambs born from sheep in panel (A) between postnatal day 1–40 (weaning) (n = 16, open diamonds,
white bars) compared to the non-pregnant adult females (n = 8, closed squares, gray bar, from panel A). (C) Plasma inorganic pyrophosphate concentration of male
(n = 9, open squares, gray bars) and female (n = 7, open circles, white bars) lambs from panel (B). MA, mother; OS, offspring; GD, gestational day; PD,
postpartum/postnatal day. Values for the data depicted were determined in experiments using at least three technical replicates. Data were analyzed using
GraphPad Prism 8.3.0. Animal groups were compared using multiple comparisons of the paired data with mixed effect models not assuming sphericity. Concomitant
Sidak’s multiple comparison tests were performed to assess significance. A female lamb was euthanized at postnatal day 15, due to a reason unrelated to the study.
Samples that showed hemolysis were not processed further and excluded from the evaluation. The exact number of samples determined for each timepoint are
presented under the corresponding bars. Data values are represented as means ± SD. Significance was accepted at p < 0.05. PPi, inorganic pyrophosphate.
non-pregnant women (1.01 ± 0.19 and 1.28 ± 0.33 µM,
respectively) (Figure 2).
Cardiovascular Disease Risk Associated
Vascular Calcification Is Increased in
Pseudoxanthoma Elasticum Patients
With Multiple Childbirths
Epidemiological data of thousands of healthy individuals indicate
that multiparous women have an elevated risk for cardiovascular
disease (Ness et al., 1993; Sanghavi et al., 2016; Kim et al., 2018;
Oliver-Williams et al., 2019; Tanigawa et al., 2019) and stroke
(Qureshi et al., 1997). Given our findings, we hypothesized that
multiple pregnancies increase cardiovascular disease risk due
to repeated, yet transitory decrease in the concentration of the
mineralization inhibitor, inorganic pyrophosphate.
Pseudoxanthoma elasticum patients have deleterious
mutations that lead to non-functional ABCC6 resulting in
chronically low plasma inorganic pyrophosphate concentrations
and, as a consequence, increased vascular calcification. PXE
patients also have higher risk of developing cardiovascular
disease and stroke (Trip et al., 2002; Köblös et al., 2010; Kauw
et al., 2017; De Vilder et al., 2018), although the latter is
debated (Hornstrup et al., 2011). We postulated, therefore,
that PXE patients with ab ovo low inorganic pyrophosphate
levels, giving birth multiple times, might have even more
pronounced vascular calcification, further increasing their risk
to develop cardiovascular disease. We tested our hypothesis
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FIGURE 2 | Plasma inorganic pyrophosphate concentration is significantly decreased in uncomplicated human pregnancy. (A) Plasma inorganic pyrophosphate
concentration versus age in pregnant (n = 13, closed circles) and non-pregnant (n = 18, open squares) healthy women. (B) Plasma inorganic pyrophosphate
concentration of healthy pregnant women (n = 13, closed circles, gray bar) at term versus non-pregnant healthy women (n = 18, open squares, white bar). Values for
the data depicted were determined at least in two independent experiments using at least three technical replicates. Data were analyzed using GraphPad Prism
8.3.0. Data in panel (B) followed normal distribution according to Kolmogorov-Smirnov test. We used unpaired two-tailed t test with Welch’s correction not assuming
equal SDs to determine significance. Bars represent means ± SD. Significance was accepted at p < 0.05. PPi, inorganic pyrophosphate.
in a cohort of PXE patients (187 individuals, 122 females),
where clinical data, including the cardiovascular disease risk
factor lower limb artery calcification (Chowdhury et al., 2017)
was studied. To assess the association between number of
childbirths to cardiovascular disease risk, we selected women
over 40 years of age with available information on parity
and lower limb artery calcification score. There was no
reported hepatic pathology, gestational diabetes, or chronic
kidney disease in any of the study subjects. One nulliparous
patient was presented with renal amyloidosis but without
any other cardiovascular risk factor. To better distinguish
patients with no or low numbers of childbirths from those
of higher number of childbirths, we excluded patients with
two childbirths, and dichotomized the remaining patients to
nulli/uniparous (n = 26; age = 54.8 ± 9.7 year) and multiparous
(>2 childbirths, n = 22; age = 59.5 ± 11.6 year) subgroups
(age, p = 0.1279). The BMI (kg/m2) values (24.9 ± 5.3 and
24.7 ± 4.2), the incidence of high blood cholesterol (30.8% ± 1.8
and 27.3% ± 2.1) and smoking (23.1% ± 1.7 and 22.8% ± 1.9)
did not differ in the nulli/unipara and multipara groups,
respectively. Amongst our included patients (Supplementary
Table 1), the lower limb artery calcification score normalized
for arterial length did not correlate with age in nulli/unipara,
and weakly correlated with age in multipara (Figure 3A).
Moreover, multiparous PXE patients had a significantly higher
normalized lower limb artery calcification score compared to
nulli/uniparous patients (p < 0.05) (Figure 3B). Thus, in these
PXE patients, parity positively correlated with elevated vascular




Correlate to Alkaline Phosphatase
Kinetics Reported in the Literature
Inorganic pyrophosphate is an important substrate of tissue
non-specific alkaline phosphatase (TNAP) (Whyte et al., 1995),
which cleaves inorganic pyrophosphate into inorganic phosphate
(Pi). According to the sheep gene expression atlas dataset1,
TNAP is highly expressed in the placenta. Moreover, TNAP
expression and alkaline phosphatase activity are dramatically
elevated in sheep during pregnancy (Healy, 1971; Clark et al.,
2017; Zywicki et al., 2018). The gradual gestational inorganic
pyrophosphate decline we observed in sheep aligns well with
these reports. Similarly, the increase in the maternal plasma
inorganic pyrophosphate concentration we observed postpartum
1http://biogps.org/sheepatlas/
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FIGURE 3 | Cardiovascular disease risk is increased in pseudoxanthoma elasticum patients giving multiple (>2) childbirths. (A) Normalized lower limb artery
calcification (nLLAC) score versus age in nulli/unipara (n = 26, open circles) and in multipara (n = 22, closed circles) with the result of a simple linear regression
performed for nLLAC score versus age in multipara. (B) nLLAC score is higher in multiparous PXE patients (n = 22, closed circles, gray bar) compared to
nulli/uniparous PXE patients (n = 26, open circles, white bar). The 48 year-old nulliparous subject with renal amyloidosis had an LLAC and nLLAC of 6,955.4 and
4.54, respectively. Data were analyzed using GraphPad Prism 8.3.0. According to Kolmogorov-Smirnov test data for panel (B) did not follow normal distribution. We
used unpaired non-parametric two-tailed Mann-Whitney test to analyze significance. Bars represent medians with 25th–75th interquartiles. Significance was
accepted at p < 0.05.
corresponds well with the decline of alkaline phosphatase activity
after parturition (Bekeova et al., 1993). Additionally, the increase
in inorganic pyrophosphate concentration in newborns aligns
with the drop in serum alkaline phosphatase activity shown
in lambs (Healy, 1971). Collectively, the alkaline phosphatase
kinetics reported in the literature provides a plausible explanation
for the dynamic plasma inorganic pyrophosphate changes we
observed in sheep.
In humans TNAP plays a pivotal role in bone metabolism by
degrading the mineralization inhibitor inorganic pyrophosphate.
TNAP defects cause hypophosphatasia, a severe skeletal/neural
disorder. Three carriers of mutant ALPL alleles coding for TNAP
had per se decreased TNAP and consequently increased plasma
inorganic pyrophosphate levels, the latter normalized during
pregnancy (Whyte et al., 1995). In parallel, the expression of
placental alkaline phosphatase (PALP), encoded by a hominid-
specific different gene, increased. As PALP also degrades
inorganic pyrophosphate (Whyte et al., 1995), the normalization
of inorganic pyrophosphate levels in the carriers was likely
due to emerging PALP activity. In healthy pregnancies, PALP
expression gradually rises and peaks at term (Sussman et al.,
1968; Okamoto et al., 1990). As a result, total serum alkaline
phosphatase activity increases approximately two-fold (Hirano
et al., 1987). Taken together, gestationally elevated PALP
activity serves as a plausible explanation for the decreased
plasma inorganic pyrophosphate concentrations we observed in
healthy pregnant women.
The evolutionary advantage of increased gestational alkaline
phosphatase activity is elusive, but it likely promotes fetal
development and growth (She et al., 2000; Liu et al., 2018). The
resulting decreased concentration of inorganic pyrophosphate is
compensated for in the healthy fetus, while elevated maternal
cardiovascular disease risk emerges only in the long term and
most likely does not affect evolutionary fitness.
Plasma Inorganic Pyrophosphate
Deficiency Is the Potential Link Between
Alkaline Phosphatase Levels and
Multiple Pregnancies, Both Contributing
to Cardiovascular Disease Risk
High alkaline phosphatase levels were previously associated
with coronary artery calcification in 500 patients (Panh et al.,
2017). Moreover, in two prospective studies involving large
cohorts of healthy individuals, baseline alkaline phosphatase
levels correlated to the future incidence of cardiovascular disease
independent of traditional cardiovascular disease risk factors
(Kunutsor et al., 2015; Kabootari et al., 2018). Finally, in meta-
analyses of ∼20,000 participants from 7 studies and ∼150,000
participants from 24 studies, elevated alkaline phosphatase
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activity was associated with increased cardiovascular disease
mortality, especially in young patients (<55 years of age) (Li
et al., 2014; Rahmani et al., 2019). On the other hand, several
epidemiological studies established that multiparous women
also have increased risk for developing cardiovascular disease
decade(s) after their pregnancies (Sanghavi et al., 2016; Kim et al.,
2018; Oliver-Williams et al., 2019; Tanigawa et al., 2019).
Our data suggest that recurrent deficiency in maternal
plasma inorganic pyrophosphate concentration, likely caused
by elevated PALP activity over subsequent pregnancies, is a
plausible mechanism for the increased cardiovascular disease
risk in multiparous women. In the above epidemiological studies
high number of subjects were studied to show the association
of cardiovascular disease risk to the number of childbirths
and, in an independent set of studies, the cardiovascular
disease risk to intrinsically high alkaline phosphatase activity.
However, we were able to show the correlation of multiple
childbirths to increased lower limb vascular calcification, an
established cardiovascular disease risk factor, in our limited set
of patients with a rare disease characterized by pathological
low plasma inorganic pyrophosphate levels. This suggests that
plasma inorganic pyrophosphate concentration is likely to
play a pivotal role in the etiology of the parity-dependent
cardiovascular disease-risk. As the mineralization inhibitor
inorganic pyrophosphate is the substrate of alkaline phosphatase
and plasma inorganic pyrophosphate concentrations decline
during pregnancy meanwhile alkaline phosphatase increases, it
therefore seems justified to conclude, that the low gestational
inorganic pyrophosphate level is the consequence of the higher
alkaline phosphatase activity, however to establish cause-effect
relationship further direct evidence is required. Moreover, it is
possible that compensatory mechanisms exist to counteract for
the gestational drop in plasma pyrophosphate concentration,
a question that further studies need to explore. Our results
demonstrate for the first time, that the maternal plasma
concentration of the major mineralization inhibitor inorganic
pyrophosphate declines during healthy pregnancy, likely due
to increased alkaline phosphatase activity. We hypothesize that
the low level of inorganic pyrophosphate is the common
denominator and putative causal link between the established
epidemiological correlations of increased cardiovascular disease
risk to multiple childbirths, on the one hand, and to
elevated alkaline phosphatase activity, on the other. Finally,
in PXE, a disorder with pathologically low plasma inorganic
pyrophosphate levels, we demonstrated that multiple childbirths
associated with increased lower limb vascular calcification,
an established risk factor for cardiovascular disease. Based
on our results and assumptions, restoration of sufficient
inorganic pyrophosphate levels during pregnancy might be a
potential prophylaxis/treatment to circumvent pregnancy-related
maternal cardiovascular disease risk both in healthy women
and in patients with compromised inorganic pyrophosphate
levels. This treatment might also potentially benefit the
children by reducing the prevalence of vascular calcification
in the next generation. However, efficacy and safety of
such application needs to be thoroughly evaluated in future
translational studies.
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